Our site has had requests to add several new insulins to formulary for use in pediatrics. There is concern for look-alike/sound-alike storage and dispensing errors by adding new formulations.
Our site was requested to add Fiasp (insulin aspart), Lyumjev (insulin lispro), Humalog U-200 (insulin lispro 200 unit/mL), and diluted Novolog (insulin aspart 10 unit/mL).
Can any sites share if they have utilized any effective strategies to minimize this risk? A few examples are noted below but would appreciate if sites can share any helpful practices.